One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients

Viviana Bazan, Lorena Incorvaia, Antonio Russo, Giuseppe Badalamenti, Carlo Messina, Alessandra Casarin, Emmanuela Musso, Ida De Luca, Maria Rita Ricciardi

Risultato della ricerca: Article

Abstract

Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT. Methods: We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3. Results: The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated. Conclusions: This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.
Lingua originaleEnglish
Numero di pagine0
RivistaSupportive Care in Cancer
Stato di pubblicazionePublished - 2019

Fingerprint

Sarcoma
Dexamethasone
Drug Therapy
Vomiting
Neurokinin-1 Receptors
Antiemetics
Serotonin Receptors
Nausea
Second Primary Neoplasms
Antineoplastic Agents
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. / Bazan, Viviana; Incorvaia, Lorena; Russo, Antonio; Badalamenti, Giuseppe; Messina, Carlo; Casarin, Alessandra; Musso, Emmanuela; De Luca, Ida; Ricciardi, Maria Rita.

In: Supportive Care in Cancer, 2019.

Risultato della ricerca: Article

@article{b5b919ff3924404fae95709e16974fb0,
title = "One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients",
abstract = "Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT. Methods: We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3. Results: The primary endpoint was reached in 88.9{\%} of patients. Cycles 2 and 3 overall CR rates were 88.9{\%} and 82.4{\%}, respectively. The antiemetic regimen was well tolerated. Conclusions: This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.",
author = "Viviana Bazan and Lorena Incorvaia and Antonio Russo and Giuseppe Badalamenti and Carlo Messina and Alessandra Casarin and Emmanuela Musso and {De Luca}, Ida and Ricciardi, {Maria Rita}",
year = "2019",
language = "English",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients

AU - Bazan, Viviana

AU - Incorvaia, Lorena

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Messina, Carlo

AU - Casarin, Alessandra

AU - Musso, Emmanuela

AU - De Luca, Ida

AU - Ricciardi, Maria Rita

PY - 2019

Y1 - 2019

N2 - Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT. Methods: We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3. Results: The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated. Conclusions: This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.

AB - Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT. Methods: We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3. Results: The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated. Conclusions: This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.

UR - http://hdl.handle.net/10447/353197

M3 - Article

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -